2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 2nd, 2025
Version: 1
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
cancer biology
biorxiv

Epigenetic Modulation, Intra-tumoral Microbiome and Immunity in Early Onset Colorectal Cancer

Jin, N.Open in Google Scholar•Hoyd, R.Open in Google Scholar•Yilmaz, A. S.Open in Google Scholar•Zhu, J.Open in Google Scholar•Liu, Y.Open in Google Scholar•Singh, M. J.Open in Google Scholar•Grencewicz, D.Open in Google Scholar•Mo, X.Open in Google Scholar•Kalady, M.Open in Google Scholar•Rosenberg, D.Open in Google Scholaret al.

Background: The incidence of colorectal cancer (CRC) in young adults (age of diagnosis < 50 years old) has been rapidly increasing. Although ~20% of early-onset (EO) CRC cases are due to germline mutations, the etiology of the majority of EOCRC cases remains poorly understood. Non-genetic factors such as environmental exposure and lifestyle changes are likely to have a direct link to the increased incidence of sporadic EOCRC. We hypothesize that such factors may be observable as differences in the EOCRC epigenome, microbiome and immunome. We sought to address this by comparing differences in DNA methylation from the cohort of colorectal cancer patients in The Cancer Genome Atlas (TCGA). Further, we carefully identified intra-tumoral microbes from TCGA and two other datasets and then related the microbes to EOCRC status and deconvolved immune cell abundances. We found that DNA methylation (DNAm) age acceleration by12 years when compared with average-onset CRC (AOCRC) patients. Differentially methylated sites associated with genes are related to CREB signaling in neurons, G protein coupled receptor signaling, phagosome formation and S100 family signaling. These differences were validated in the gene expression from TCGA and a second, larger real-world dataset from the Oncology Research Information Exchange Network (ORIEN). However, no consistent differences were observed in the intra-tumor microbes between EOCRC and AOCRC. Interestingly, the most abundant microbes interacted with the immune systems differently between the EOCRC and AOCRC tumors, characterized by more, larger, positive correlations in EOCRC. These data suggest epigenetic modulation and accelerated aging may play a key role in the development of EOCRC.

Similar Papers

biorxiv
Thu Apr 03 2025
Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1
Chimeric antigen receptor CAR T cell therapy faces notable limitations in treatment of solid tumors. The suppressive tumor microenvironment TME, characterized by complex interactions among immune and stromal cells, is gaining recognition in conferring resistance to CAR T cell therapy. Despite the abundance and diversity of macrophages in the TME, their intricate involvement in modulating responses...
Gholamin, S.
•
Natri, H. M.
•
Zhao, Y.
•
Xu, S.
...•
Brown, C.
biorxiv
Wed Apr 02 2025
Futile wound healing drives mesenchymal-like cell phenotypes in human glioblastoma
Glioblastoma is the deadliest brain cancer, characterized by large cellular diversity whose complexity and organizing principles are only starting to be uncovered. Both neurodevelopment-like and mesenchymal-like cell states have been described in glioblastoma, with the latter being strongly implicated in malignancy and disease progression. However, the nature of these mesenchymal-like cell states ...
Mossi Albiach, A.
•
Janusauskas, J.
•
Kjaer Jacobsen, J.
•
Kapustova, I.
...•
Linnarsson, S.
biorxiv
Wed Apr 02 2025
Loss-of-Function genetic Screen Unveils Synergistic Efficacy of PARG Inhibition with Combined 5-Fluorouracil and Irinotecan Treatment in Colorectal Cancer
Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease. The combination of 5-Fluorouracil (5FU, a thymidylate synthase inhibitor) and irinotecan (a topoisomerase 1 inhibitor) is widely used in first-line and subsequent treatments. This study aims to identify novel therapeutic targets to enhanc...
Queralt, C.
•
Moreta-Moraleda, C.
•
Costa, M.
•
Grau-Leal, F.
...•
Martinez-Balibrea, E.
biorxiv
Wed Apr 02 2025
Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptides
KRAS is a proto-oncogene that contains activating mutations in up to 30% of tumors. Many conventional therapies inhibit both cancerous and normal cells, which may cause toxicity. Thus, programmable mutant-selective targeted inhibitors are needed. Peptide nucleic acids (PNAs) incorporate base sequences analogous to DNA, with modified peptide backbones instead of ribose-phosphate backbones, allowing...
Mondal, J.
•
Lam, D.
•
Gerritsen, M. E.
•
Brotz, T. M.
...•
Wolfe, A. L.
biorxiv
Wed Apr 02 2025
Attention Guided Mechanism Interpretable Drug-Gene Interaction (MIDI) Modeling for Cancer Drug Response Prediction and Target Effect Explanation
Cancer drug discovery using genetic information is still poorly developed. Precisely locating drug atoms and explaining the targeting effect is crucial in precision medicine since it helps understand the drug\'s mechanism of action. Much data has been collected regarding drug response against cancer cell lines, and many models predict the drug response based on genomic information. However, to our...
Wanyan, T.
•
Cai, L.
•
Nijhawan, D.
•
Posner, B.
...•
Xie, Y.
biorxiv
Wed Apr 02 2025
Relationship between melanoma vemurafenib tolerance thresholds and metabolic pathway choice and Wnt signaling involvement
Vemurafenib constitutes an important therapeutic for BRAFV600 mutant melanomas, but despite high initial response rates, resistance to BRAF and MEK inhibitors quickly develops. Here, we performed an integrative analysis of metabolomic consequences and transcriptome alterations to uncover mechanisms involved in adaptive vemurafenib resistance (VemR) development and their relationship with vemurafen...
Nangia-Makker, P.
•
Ahrens, M.
•
Purandare, N.
•
Aras, S.
...•
Shekhar, M. P.
biorxiv
Wed Apr 02 2025
Substrate stiffness regulates triple-negative breast cancer signaling through CXCR4 receptor dynamics
Biophysical properties of the extracellular matrix (ECM), such as mechanical stiffness, directly regulate behaviors of cancer cells linked to cancer initiation and progression. Cells sense and respond to ECM stiffness in the context of dynamic changes in biochemical inputs, such as growth factors and chemokines. While commonly studied as isolated inputs, mechanisms by which combined effects of mec...
Ho, K. K. Y.
•
Buschhaus, J. M.
•
Zhang, A.
•
Cutter, A. C.
...•
Luker, G. D.
biorxiv
Wed Apr 02 2025
Lack of consistent effect of dietary fiber on immune checkpoint blockade efficacy across diverse murine tumor models
Immune checkpoint blockade (ICB) has transformed cancer treatment, but success rates remain low in most cancers. Recent research suggest that dietary fiber enhances ICB response in melanoma patients and murine preclinical models through microbiome-dependent mechanisms. Yet, the robustness of this effect across cancer types and dietary contexts remains unclear. Specifically, prior literature compar...
Roichman, A.
•
Reyes-Castellanos, G.
•
Chen, Z.
•
Chen, Z.
...•
Rabinowitz, J. D.
biorxiv
Wed Apr 02 2025
Cell and nuclear size are associated with chromosomal instability and tumorigenicity in cancer cells that undergo whole genome doubling
Whole genome doubling (WGD) is a frequent event in cancer evolution associated with chromosomal instability, metastasis, and poor prognosis. While the genomic consequences of WGD are well documented, the effects of non-genetic alterations that accompany WGD, such as changes to cell and nuclear size, on tetraploid (4N) cancer cell physiology are less understood. Here, we show that cell and nuclear ...
Bloomfield, M.
•
Huth, S.
•
McCausland, D.
•
Saad, R.
...•
Cimini, D.